Miriana Di Stefano, Samuele Masoni, Giulia Bononi, Giulio Poli, Salvatore Galati, Francesca Gado, Simone Manzi, Chiara Vagaggini, Annalaura Brai, Isabella Caligiuri, Kanwal Asif, Flavio Rizzolio, Marco Macchia, Andrea Chicca, Andrea Sodi, Valeria Di Bussolo, Filippo Minutolo, Philip Meier, Jürg Gertsch, Carlotta Granchi, Elena Dreassi, Tiziano Tuccinardi
European journal of medicinal chemistry 2024 Jan 05The degradation of the endocannabinoid 2-arachidonoylglycerol is mediated by the enzyme monoacylglycerol lipase (MAGL), thus generating arachidonic acid, the precursor of prostaglandins and other pro-inflammatory mediators. MAGL also contributes to the hydrolysis of monoacylglycerols into glycerol and fatty acids in peripheral body districts, which may act as pro-tumorigenic signals. For this reason, MAGL inhibitors have been considered as interesting therapeutic agents for their anti-nociceptive, anti-inflammatory, antioxidant and anti-cancer properties. So far, only a limited series of reversible MAGL inhibitors, which are devoid of side effects shown by irreversible inhibitors in animal models, have been reported. Here we optimized a class of benzylpiperidine and benzylpiperazine-based compounds for a reversible MAGL inhibition. The best MAGL inhibitors of this class, compounds 28 and 29, showed a very good inhibition potency, both on the isolated enzyme and in U937 cells, as confirmed by molecular modeling studies that predicted their binding mode into the MAGL active site. Both compounds are characterized by a high selectivity for MAGL versus other serine hydrolases including enzymes of the endocannabinoid system, as confirmed by ABPP experiments in mouse brain membranes. Moreover, very good properties concerning ADME parameters and low in vivo toxicity have been observed for both compounds. Copyright © 2023 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Miriana Di Stefano, Samuele Masoni, Giulia Bononi, Giulio Poli, Salvatore Galati, Francesca Gado, Simone Manzi, Chiara Vagaggini, Annalaura Brai, Isabella Caligiuri, Kanwal Asif, Flavio Rizzolio, Marco Macchia, Andrea Chicca, Andrea Sodi, Valeria Di Bussolo, Filippo Minutolo, Philip Meier, Jürg Gertsch, Carlotta Granchi, Elena Dreassi, Tiziano Tuccinardi. Design, synthesis, ADME and biological evaluation of benzylpiperidine and benzylpiperazine derivatives as novel reversible monoacylglycerol lipase (MAGL) inhibitors. European journal of medicinal chemistry. 2024 Jan 05;263:115916
PMID: 37976705
View Full Text